Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 378 SAD, MAD, and Food-effect Study in Healthy Participants
NCT06910709Phase 1Terminated
- Sponsor
- Amgen
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 378 (3 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent Adverse Event at Day 40. Started Apr 2025; status: terminated.
02
Drugs
AMG 378
Beyond the preview
Go deeper on NCT06910709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910709.